The specificity of T cell recognition is determined by the variable (V) domain of the T cell receptor (TCR ... our efforts on solving the crystal structure of a mouse TCR in complex with an ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nature Cancer , 2025; DOI: 10.1038/s43018-025-00934-1 Cite ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

In recent years, CAR-T cell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. In combination with other tools (chemotherapy, radiotherapy), this new ...

This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients. Researchers said they identified a particular set of adverse effects in ...

Get Instant Summarized Text (Gist) A novel approach using CAR-M (Chimeric Antigen Receptor Macrophages) has been developed to address the limitations of CAR-T therapy in treating solid tumors. By ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types ...

Chimeric antigen receptor (CAR) T-cell therapies have drastically changed treatment paradigms in relapsed and refractory (R/R) haematological malignancies since the approval of the first CAR-T ...